The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Lerner Neil since 2011.
This trader's CIK number is 1505148.
At the time of last reporting, Lerner Neil was the CHIEF ACCOUNTING OFFICER of Compass Therapeutics, Inc.. (stock ticker symbol CMPX).
Also see all insider trading activities at Compass Therapeutics, Inc..
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2025 | CMPX | 20,000 | $28,400 | 0 | $0 | 0 | $0 |
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2019 | PMD | 0 | $0 | 9,057 | $136,779 | 0 | $0 |
2018 | PMD | 0 | $0 | 4,892 | $98,242 | 0 | $0 |
2016 | PMD | 0 | $0 | 3,000 | $74,250 | 0 | $0 |
2015 | PMD | 3,000 | $30,960 | 0 | $0 | 0 | $0 |
2012 | PMD | 2,500 | $24,500 | 0 | $0 | 0 | $0 |
2011 | PMD | 7,895 | $77,190 | 0 | $0 | 0 | $0 |
1. Compass Therapeutics, Inc. (CMPX)
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2025-04-07 | CMPX | Buy | 20,000 | 1.42 | 28,400 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2019-03-12 | PMD | Sale | 1,412 | 15.06 | 21,264 |
2019-03-11 | PMD | Sale | 7,645 | 15.11 | 115,515 |
2018-05-21 | PMD | Sale | 3,013 | 20.14 | 60,681 |
2018-05-22 | PMD | Sale | 1,879 | 19.99 | 37,561 |
2016-11-18 | PMD | Sale | 3,000 | 24.75 | 74,250 |
2015-09-10 | PMD | Buy | 3,000 | 10.32 | 30,960 |
2012-06-15 | PMD | Buy | 2,500 | 9.80 | 24,500 |
2011-05-25 | PMD | Buy | 5,895 | 10.01 | 59,008 |
2011-03-17 | PMD | Buy | 2,000 | 9.09 | 18,182 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Lerner Neil (CHIEF ACCOUNTING OFFICER of Compass Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.